Your Cart Is Empty!
Approved by the FDA in February on the strength of impressive Phase II data from the PALOMA-1 study, Pfizers CDK4/6 inhibitor Ibrance is poised to transform the way that HER2-negative/HR-positive breast cancer is treated, suggest key opinion leaders.
Supporting this view, prescription data indicate strong uptake of Ibrance since launch, discussion of which is likely to form a key component of Pfizers second quarter earnings report later this month.
Initially approved for use in the first-line setting, Ibrance has also demonstrated progression free survival (PFS) benefit in second-line patients, which prompted Pfizer to confirm an early stop to thePALOMA-3 study in April. While confirmatory from the Phase III PALOMA-2 is necessary to support the FDAs accelerated approval procedure for Ibrance, Pfizers product looks strongly positioned to gain notable market entrenchment ahead of competitor CDK4/6 inhibitors being developed by Eli Lilly and Novartis.
With Ibrance having now been available for some months in the US market, and with the product poised to be one of the largest new drug approvals of 2015, FirstWord is polling oncologists with the following questions
- In your experience with Ibrance (palbociclib) to date, how would you characterise efficacy?
- In your experience with Ibrance (palbociclib) to date, how would you characterise safety/tolerability?
- Over the next 12 months, how do you expect your usage of Ibrance to change?
- In 12 months time, in what percentage of HER2-negative/HR-positive breast cancer patients would you expect to be using Ibrance as a first-line therapy?
- In 12 months time, in what percentage of HER2-negative/HR-positive breast cancer patients would you expect to be using Ibrance as a second-line therapy?
Following are different modes of Licenses.
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]
2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.